Name: Dr. med. Alexander Balck

Address: Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Phone: +49 451 3101 8201

Email: alexander.balck@uni-luebeck.de

Research fellow at the Institute of Neurogenetics, University of Lübeck

Resident at the Department of Neurology, University of Lübeck

2009 – 2015: Medical School (University of Lübeck and University Göttingen)

2015 – 2016: Final year studies (Surgery: Montreal General Hospital, Mc Gill University, Canada; Internal Medicine: University of Galle, Sri Lanka; Neurology: University of Göttingen, Germany)

2011 – 2013: Medical Thesis: Laboratory of Prof. Paul Lingor, MD, Dept. of Neurology, Göttingen “Combination treatment with fasudil and riluzole in the SOD1-G93A mouse model of amyotrophic lateral sclerosis”)

2016 – 2017: Research fellowship at the Institute of Neurogenetics, University of Lübeck, Germany

2017 – present: Medical residency at the Dept. of Neurology, University of Lübeck, Germany

2018 – 2019: Research fellowship at the Institute of Neurogenetics, University of Lübeck, Germany

2020: Management of the ELISA study center (elisa-luebeck.de)

2021 – 2022: Research fellowship at the Leiden Amsterdam Center for Drug Research (LACDR), Leiden University, Netherlands, Supervisor: Prof. Thomas Hankemeier

Stipends and Scholarships:

• German Society of Neurology (DGN)
• Parkinson and Movement Disorders Society (MDS)

• Annals of Neurology
• Movement Disorders

• Current MD Theses in preparation n=2

1. Borsche M, Märtens A, Hörmann P, Brückmann T, Lohmann K, Tunc S, Klein C, Hiller K, Balck A. In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN-Related Parkinson's Disease. Movement Disorders : official Journal of The Movement Disorder Society 2023;in press.
2. Balck A, Föh B, Borsche M, Rahmöller J, Vollstedt EJ, Waldeck F, Käding N, Twesten C, Mischnik A, Gillessen-Kaesbach G, Ehlers M, Sina C, Taube S, Busch H, Rupp J, Katalinic A, Klein C. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study. BMC Public Health 2022;1:1305.
3. Klein C, Borsche M, Balck A, Föh B, Rahmöller J, Peters E, Knickmann J, Lane M, Vollstedt EJ, Elsner SA, Käding N, Hauswaldt S, Lange T, Hundt JE, Lehrian S, Giese J, Mischnik A, Niemann S, Maurer F, Homolka S, Paulowski L, Kramer J, Twesten C, Sina C, Gillessen-Kaesbach G, Busch H, Ehlers M, Taube S, Rupp J, Katalinic A. One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk. Sci Adv 2022;15:eabm5016.
4. Gabbert C, König IR, Lüth T, Kolms B, Kasten M, Vollstedt EJ, Balck A, Grünewald A, Klein C, Trinh J. Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson's disease. J Neurol 2022;8:4195-4203.
5. Balck A, Schaake S, Kuhnke NS, Domingo A, Madoev H, Margolesky J, Dobricic V, Alvarez-Fischer D, Laabs BH, Kasten M, Luo W, Nicolas G, Marras C, Lohmann K, Klein C, Westenberger A. Genotype-Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review. Mov Disord 2021;11:2468-2480.
6. Borsche M, Reichel D, Fellbrich A, Lixenfeld AS, Rahmöller J, Vollstedt EJ, Föh B, Balck A, Klein C, Ehlers M, Moser A. Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19. Neurol Res Pract 2021;1:34.
7. Trilck-Winkler M, Borsche M, König IR, Balck A, Lenz I, Kasten M, Lohmann K, Brockmann K, Valente EM, Klein C, Brüggemann N, Seibler P. Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease. Mov Disord 2021;1:271-273.
8. Föh B, Borsche M, Balck A, Taube S, Rupp J, Klein C, Katalinic A. Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic? Eur Respir J 2020;4
9. Dulovic-Mahlow M, König IR, Trinh J, Diaw SH, Urban PP, Knappe E, Kuhnke N, Ingwersen LC, Hinrichs F, Weber J, Kupnicka P, Balck A, Delcambre S, Vollbrandt T, Grünewald A, Klein C, Seibler P, Lohmann K. Discordant Monozygotic Parkinson Disease Twins: Role of Mitochondrial Integrity. Ann Neurol 2020;1:158-164.
10. Borsche M, König IR, Delcambre S, Petrucci S, Balck A, Brüggemann N, Zimprich A, Wasner K, Pereira SL, Avenali M, Deuschle C, Badanjak K, Ghelfi J, Gasser T, Kasten M, Rosenstiel P, Lohmann K, Brockmann K, Valente EM, Youle RJ, Grünewald A, Klein C. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain 2020;10:3041-3051.
11. Balck A, Borsche M, Grütz K, Brüggemann N, Westenberger A, Klein C, Alvarez-Fischer D. Don't do harm by diagnosis – An abnormal cranial CT: Still fa(h)r from a disease. Parkinsonism Relat Disord 2020:116-118.
12. Dulovic-Mahlow M, Lukomska A, Diaw SH, Balck A, Borsche M, Grütz K, Lenz I, Rudolph F, Lohmann K, Klein C, Seibler P. Generation and characterization of human-derived iPSC lines from three pairs of monozygotic twins discordant for Parkinson's disease. Stem Cell Res 2019:101629.
13. Borsche M, Balck A, Kasten M, Lohmann K, Klein C, Brüggemann N. The sooner, the later – Delayed diagnosis in Parkinson's disease due to Parkin mutations. Parkinsonism Relat Disord 2019:284-285.
14. Balck A, Borsche M, Kasten M, Lohmann K, Seibler P, Brüggemann N, Klein C. Discordance in monozygotic Parkinson's disease twins – continuum or dichotomy? Ann Clin Transl Neurol 2019;6:1102-1105.
15. Westenberger A, Balck A, Klein C. Primary familial brain calcifications: genetic and clinical update. Curr Opin Neurol 2019;4:571-578.
16. Trinh J, Lohmann K, Baumann H, Balck A, Borsche M, Brüggemann N, Dure L, Dean M, Volkmann J, Tunc S, Prasuhn J, Pawlack H, Imhoff S, Lill CM, Kasten M, Bauer P, Rolfs A, International Parkinson's Disease Genomics Consortium (IPDGC), Klein C. Utility and implications of exome sequencing in early-onset Parkinson's disease. Mov Disord 2018;1:133-137.
17. Dulovic M, Schäffer E, Leypoldt F, Balck A, Schaake S, Hinrichs F, Kirchner H, Brüggemann N, Berg D, Lohmann K. A Klinefelter patient with an additional mitochondrial mutation: Implications for genotype-driven treatment and mitochondrial mutational load in different tissues and family members. Parkinsonism Relat Disord 2018:116-118.
18. Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt EJ, Balck A, Domingo A, Vulinovic F, Dulovic M, Zorn I, Madoev H, Zehnle H, Lembeck CM, Schawe L, Reginold J, Huang J, König IR, Bertram L, Marras C, Lohmann K, Lill CM, Klein C. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord 2018;5:730-741.
19. Balck A, Tunc S, Schmitz J, Hollstein R, Kaiser FJ, Brüggemann N. A Novel Frameshift CACNA1A Mutation Causing Episodic Ataxia Type 2. Cerebellum 2018;4:504-506.
20. Balck A, Hanssen H, Hellenbroich Y, Lohmann K, Münchau A. Adult-onset ataxia or developmental disorder with seizures: two sides of missense changes in CACNA1A. J Neurol 2017;7:1520-1522.
21. Balck A, Klein C. Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection. Mov Disord 2017;4:527.
22. Günther R, Balck A, Koch JC, Nientiedt T, Sereda M, Bähr M, Lingor P, Tönges L. Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset. Front Pharmacol 2017:17.
23. Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 2013;2:217-232.